摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

卢帕他定杂质 | 169253-15-0

中文名称
卢帕他定杂质
中文别名
——
英文名称
8-CHLORO-11-(4-PIPERIDINYL)-11H-BENZO[5,6]CYCLOHEPTA(1,2-b)PYRIDINE
英文别名
8-Chloro-11-(4-Piperidinyl)-11H-Benzo[5,6]Cyclo-Hepta[1,2-b]Pyridine;8-CHLORO-11-(4-PIPERIDINYL)-11H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINE;13-Chloro-2-piperidin-4-yl-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaene
卢帕他定杂质化学式
CAS
169253-15-0
化学式
C19H19ClN2
mdl
——
分子量
310.826
InChiKey
SVSXQBQHBNRAPC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    485.1±45.0 °C(Predicted)
  • 密度:
    1.202±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    22
  • 可旋转键数:
    1
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.32
  • 拓扑面积:
    24.9
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Potent, Selective, and Orally Bioavailable Tricyclic Pyridyl Acetamide N-Oxide Inhibitors of Farnesyl Protein Transferase with Enhanced in Vivo Antitumor Activity
    摘要:
    We previously reported compound 1 as a potent farnesyl protein transferase (FPT) inhibitor that exhibited reasonable pharmacokinetic stability and showed moderate in vivo activity against a variety of tumor cell lines. The analogous C-11 single compound, pyridylacetamide 2, was found to be more potent than 1 in FPT inhibition. Further studies showed that modification of the ethano bridge of the tricyclic ring system by conversion into a double bond with concomitant introduction of a single bond at C-11 piperidine resulted in compound 3 that had superior FPT activity and pharmacokinetic stability. Compound 4, a 5-bromo-substituted analogue of 3, showed improved FPT activity, had good cellular activity, and demonstrated a remarkably improved pharmacokinetic profile with AUC of 84.9 and t(1/2) of 82 min. Compound 4 inhibited the growth of solid tumor in DLD-1 model by 70% at 50 mpk and 52% at 10 mpk.
    DOI:
    10.1021/jm980013b
  • 作为产物:
    描述:
    地氯雷他定三氟甲磺酸sodium hydroxide 作用下, 以 为溶剂, 反应 216.0h, 生成 卢帕他定杂质
    参考文献:
    名称:
    Novel farnesyl protein transferase inhibitors as antitumor agents
    摘要:
    揭示了由式(1.0)表示的新型三环化合物: 1 或其药学上可接受的盐或溶剂。这些化合物对抑制法尼基蛋白转移酶具有用处。还揭示了包括式1.0化合物的药物组合物。还揭示了使用式1.0化合物治疗癌症的方法。
    公开号:
    US20030229099A1
点击查看最新优质反应信息

文献信息

  • Tricyclic amide and urea compounds useful for inhibition of G-protein
    申请人:Schering Corporation
    公开号:US05700806A1
    公开(公告)日:1997-12-23
    Novel compounds of Formula (7.0a), (7.0b) or (7.0c): ##STR1## are disclosed. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering a compound of the formula (7.0a), (7.0b) or (7.0c) to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being.
    揭示了化合物的新颖结构,其化学式为(7.0a)、(7.0b)或(7.0c):##STR1##。还揭示了一种抑制Ras功能从而抑制细胞异常生长的方法。该方法包括向生物系统施用化合物的化学式(7.0a)、(7.0b)或(7.0c)。具体而言,该方法抑制了哺乳动物(如人类)中细胞的异常生长。
  • Tricyclic carbamate compounds useful for inhibition of G-protein
    申请人:Schering Corporation
    公开号:US06075025A1
    公开(公告)日:2000-06-13
    A method of inhibiting Ras function and therefore inhibiting cellular growth is disclosed. The method comprises the administration of a compound of Formula 1.0 ##STR1## Also disclosed are novel compounds of the formulas: ##STR2## Also disclosed are processes for making 3-substituted compounds of the Formulas 1.1, 1.2 and 1.3. Further disclosed are novel compounds which are intermediates in the processes for making the 3-substituted compounds of Formulas 1.1, 1.2, and 1.3.
    揭示了一种抑制Ras功能从而抑制细胞生长的方法。该方法包括给予Formula 1.0的化合物。还揭示了以下公式的新化合物:还揭示了制备公式1.1、1.2和1.3的3-取代化合物的方法。进一步揭示了在制备公式1.1、1.2和1.3的3-取代化合物的过程中的新化合物。
  • Tricyclic amide and urea compounds useful for inhibition of g-protein
    申请人:Schering Corporation
    公开号:US05719148A1
    公开(公告)日:1998-02-17
    A method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells is disclosed. The method comprises the administration of a compound of Formula 1.0: ##STR1## to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being. Novel compounds of formulas 5.0, 5.1 and 5.2, wherein R is --C(R.sup.20)(R.sup.21)(R.sup.46), and 5.3, 5.3A and 5.3B, wherein R is --N(R.sup.25)(R.sup.48), are disclosed. Also disclosed are processes for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3. Further disclosed are novel compounds which are intermediates in the process for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3.
    抑制Ras功能从而抑制细胞异常生长的方法已被披露。该方法包括向生物系统中施用Formula 1.0的化合物:##STR1##。具体来说,该方法抑制了哺乳动物(如人类)中细胞的异常生长。还披露了Formula 5.0、5.1和5.2的新化合物,其中R为--C(R.sup.20)(R.sup.21)(R.sup.46),以及Formula 5.3、5.3A和5.3B,其中R为--N(R.sup.25)(R.sup.48)。还披露了制备Formula 5.0、5.1、5.2和5.3的3-取代化合物的方法。此外,还披露了在制备Formula 5.0、5.1、5.2和5.3的3-取代化合物过程中的中间体新化合物。
  • Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
    申请人:——
    公开号:US20020068742A1
    公开(公告)日:2002-06-06
    A method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells is disclosed. The method comprises the administration of a compound of Formula 1.0: 1 to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being. Novel compounds of the formulas 2 are disclosed. Also disclosed are processes for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3. Further disclosed are novel compounds which are intermediates in the process for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3.
    本发明揭示了一种抑制Ras功能,从而抑制细胞异常生长的方法。该方法包括向生物系统中给予1.0:1化合物的管理。特别是,在哺乳动物如人类中,该方法抑制细胞异常生长。还揭示了公式2的新化合物。还揭示了制备公式5.0、5.1、5.2和5.3的3-取代化合物的过程。此外,还揭示了在制备公式5.0、5.1、5.2和5.3的3-取代化合物的过程中的新化合物,这些新化合物是中间体。
  • Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
    申请人:SCHERING CORPORATION
    公开号:EP1123931A1
    公开(公告)日:2001-08-16
    A method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells is disclosed. The method comprises the administration of a compound of formula (1.0) to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being. Novel compounds of formulae (5.0, 5.1, 5.2, 5.3, 5.3A and 5.3B) are disclosed. Also disclosed are process for making the 3-substituted compound of formulae (5.0, 5.1, 5.2 and 5.3). Further disclosed are novel compounds which are intermediates in the process for making 3-substituted compounds of formulae (5.0, 5.1, 5.2 and 5.3).
    本发明公开了一种抑制 Ras 功能从而抑制细胞异常生长的方法。该方法包括向生物系统施用式(1.0)化合物。特别是,该方法可抑制哺乳动物如人体内细胞的异常生长。本发明公开了式(5.0、5.1、5.2、5.3、5.3A 和 5.3B)的新型化合物。还公开了式 (5.0、5.1、5.2 和 5.3) 的 3-取代基化合物的制造工艺。还公开了作为式(5.0、5.1、5.2 和 5.3)3-取代化合物制造工艺中间体的新型化合物。
查看更多

同类化合物

马来酸阿扎他啶 脱羧氯雷他定杂质B 盐酸氯雷他定 盐酸氯雷他定 洛那法尼 氯雷他定脱氯杂质 氯雷他定环氧化物 氯雷他定杂质I 氯雷他定杂质F 氯雷他定杂质C 氯雷他定杂质50 氯雷他定杂质29 氯雷他定杂质26 氯雷他定杂质17 氯雷他定杂质14 氯雷他定杂质1 氯雷他定杂质 氯雷他定8-溴代杂质 氯雷他定 托吡林 富马酸卢帕他定 地氯雷他定杂质14 地氯雷他定杂质1 地氯雷他定异构体 地氯雷他定-D4 地氯雷他定 去氯雷他定-N-羟基哌啶 卢帕他定杂质C 卢帕他定杂质B 卢帕他定杂质2 卢帕他定杂质 卢帕他定 乙基4-[8-氯-4-(羟基甲基)-5,6-二氢-11H-苯并[5,6]环庚并[1,2-b]吡啶-11-亚基]-1-哌啶羧酸酯 乙基4-(8-氯-3-羟基-5,6-二氢-11H-苯并[5,6]环庚并[1,2-b]吡啶-11-亚基)-1-哌啶羧酸酯 乙基4-(8-氯-3-甲氧基-5,6-二氢-11H-苯并[5,6]环庚并[1,2-b]吡啶-11-亚基)-1-哌啶羧酸酯 乙基4-(8-氯-1-氧代-5,6-二氢-11H-苯并[5,6]环庚并[1,2-b]吡啶-11-亚基)-1-哌啶羧酸酯 [4-(8-氯-5,6-二氢-11H-苯并[5,6]环庚[1,2-b]吡啶基-11亚烷基)-1-哌啶基](1H-1,2,4-三唑-1-基)甲酮 N-甲酰基地氯雷他定 N-亚硝基地氯雷他定 N-乙酰基地氯雷他定 D3-3-氧代丁酸甲酯 8-脱氯-9-氯氯雷他定 8-脱氯-9-氯地氯雷他定 8-脱氯-9-氯-N-甲基地氯雷他定 8-氯-6,11-二氢-11-(4-哌啶基亚基)-5H-苯并[5,6]环庚三烯并[1,2-B]吡啶-2,3,4,5,5-D5 8-氯-6,11-二氢-11-(1-甲基-4-哌啶基)-5H-苯并[5,6]环庚烷[1,2-b]吡啶-11-醇 8-氯-6,11-二氢-11-(1-甲基-4-哌啶叉)-5H-苯并[5,6]环庚烷[1,2-b]吡啶 8-氯-5,6-二氢-11H-苯并[5,6]环庚烷并[1,2-b]吡啶-11-酮 8-氯-5,6-二氢-11H-苯并[5,6]环庚并[1,2-b]吡啶-11-酮 1-氧化物 8-氯-3-甲氧基-5,6-二氢-11H-苯并[5,6]环庚并[1,2-b]吡啶-11-酮